Potentially life-threatening intravenous acetaminophen overdose in a 3-month-old (40 weeks’ post-menstrual age), 2.3 kg baby girl

Shane Campbell, Thomas Engelhardt, James McLay, Brian Anderson

Department of Anaesthesia, Royal Aberdeen Children’s Hospital, Aberdeen, UK.
Intensive Care Medicine, Auckland Children’s Hospital, Auckland, New Zealand.

DOI: 10.4236/ojped.2013.33032                

Abstract

A case is presented of a serious, potentially life-threatening intravenous acetaminophen overdose in a 3-month-old (40 weeks’ post menstrual age),2.3 kgbaby girl. The neonate was scheduled for urgent laser therapy for retinopathy of prematurity. Instead of an intended intravenous Hartmann’s solution bolus of 10 ml·kgˉ¹, the neonate received a 17 ml bolus of correctly labelled intravenous 1% acetaminophen. The National Poisons Bureau was immediately contacted for advice and in the absence of data suggested a treatment with N-acetylcysteine for a 24-hour period. Baseline blood samples for clotting, liver function, urea and electrolytes, full blood count and plasma acetaminophen concentration were taken 30 min, 8.25 h, 12.5 h, 18.5 h and 120 h after the overdose. Acetaminophen concentration was 78 mg·Lˉ¹ at 30 min, but it was undetectable at any other time. Using a recent and complete PK-PD dataset we are able to show that the measured plasma acetaminophen concentration fits well on PK estimates for acetaminophen in this neonate. The non-detectable (low) plasma acetaminophen concentration at >8 h is also consistent with this model, especially if clearance is slightly increased in the premature nursery graduate. Medical errors are rarely the fault of an individual and they are often due to a combination of factors. Contributing factors, in this case, are described under the following headings: Catalyst event, system fault, loss of situational awareness, and human error.

Keywords

Neonate; Acetaminophen Overdose; No Sequelae; PK Models; Drug Error

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Allegaert, K., Palmer, G.M. and Anderson, B.J. (2011) The pharmacokinetics of intravenous paracetamol in neonates: Size matters most. Archives of Disease in Childhood, 96, 575-580. doi:10.1136/adc.2010.204552
[2]	Anderson, B.J., Woollard, G.A. and Holford, N.H.G. (2000) A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. British Journal of Clinical Pharmacology, 50, 125-134. doi:10.1046/j.1365-2125.2000.00231.x
[3]	Allegaert, K., Anderson, B.J., Naulears, G., de Hoon, J., Debeer, A., Devlieger, H. and Tibboel, D. (2004) Intravenous paracetamol (propacetamol) pharmacokinetics in premature neonates. European Journal of Clinical Pharmacology, 60, 191-197. doi:10.1007/s00228-004-0756-x
[4]	Porta, R., Sánchez, L., Nicolás, M., Garcia, C. and Martinez, M. (2012) Lack of toxicity after paracetamol overdose in an extremely preterm neonate. European Journal of Clinical Pharmacology, 68, 901-902. doi:10.1007/s00228-011-1165-6
[5]	Anderson, B.J., Pons, G., Autret-Leca, E., Allegaert, K. and Boccard, E. (2005) Paediatric intravenous paracetamol (propacetamol) pharmacokinetics; a population analysis. Pediatric Anesthesia, 15, 282-292. doi:10.1111/j.1460-9592.2005.01455.x
[6]	Anderson, B.J., van Lingen, R.A., Hansen, T.G., Lin, Y.-C. and Holford, N.H.G. (2002) Acetaminophen developmental pharmacokinetics in premature neonates and infants: A pooled population analysis. Anesthesiology, 96, 1336-1345. doi:10.1097/00000542-200206000-00012